Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines

Viewpoint notes that once authorized vaccines become widely available, conducting placebo-controlled trials of subsequent vaccine candidates may become challenging; alternative strategies to evaluate those vaccines against authorised products, are needed.

Source:

Journal of the American Medical Association